ArticleFrontiers in oncology2026
Prognostic factors and outcomes of CT-guided Iodine-125 seed brachytherapy for retroperitoneal lymph node metastases from a previously irradiated field in cervical carcinoma: a multicenter retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective study aimed to evaluate the efficacy, safety, and prognostic factors of Iodine-125 seed brachytherapy for Retroperitoneal Lymph Node Metastases (RLNM) from a Previously Irradiated Field in Cervical Carcinoma. Methods: Between March 2020 and November 2024, 33 patients (40 lesions) with RLNM from Cervical Carcinoma, who were ineligible for or declined further external beam radiotherapy (EBRT), underwent CT-guided iodine-125 seed brachytherapy at three tertiary hospitals. The follow-up deadline was 28/02/2026. The following endpoints were assessed: disease control rate (DCR), local tumor progression-free survival (LTPFS), overall survival (OS), and adverse events. Results: The median follow-up time was 18.6 months (range, 2.0-38.3 months), and the 3- and 6- month DCR was 90.0% and 77.5%, respectively. The median LTPFS was 9.0 months (IQR, 5.3 - 20.5), and the median OS was 20.0 months (IQR, 8.0 - 25.0). The 6-, 12-, 18- and 24- month survival rates were 81.8%, 60.5%, 50.2%, 28.2%, respectively. Among 8 patients with preoperative pain, the Numerical Rating Scale (NRS) score decreased from 3.50 ± 1.77 to 1.75 ± 1.49 one month postoperatively (t=3.564, P = 0.009), a statistically significant difference. One patient developed a sigmoid colon fistula 4 months postoperatively. Four patients experienced postoperative low back discomfort with NRS scores of 1-2, which was relieved spontaneously or with oral analgesics. Multivariate analysis using the Cox proportional hazards model showed that a dose to 90% of the gross tumor volume (D90) ≥ 108 Gy was a protective factor for LTPFS, and tumor invasion of the intestinal wall was a risk factor for OS. Conclusion: Iodine-125 seed brachytherapy is safe and effective for treating RLNM in Cervical Carcinoma. A D90 ≥ 108 Gy results in better LTPFS. Tumor invasion of the intestinal wall is a risk factor for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.